Tag Archives: Postpartum

FDA Supports Intravenous Brexanolone for Postpartum Depression

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABAA receptors.  Since that time, Sage Therapeutics has conducted three randomized controlled trials, enrolling a total of 247 women diagnosed with moderate to severe postpartum depression. This… Read More »

New Study at CWMH: Genetics of Postpartum Psychosis – Massachusetts General Hospital Postpartum Psychosis Project (MGHP3)

Postpartum psychosis (PPP) is a rare but serious condition, occurring in 1 to 2 per 1000 women in the weeks after delivery and associated with extreme delirium-like behavior, delusions, hallucinations, and an increased risk of suicide and infanticide.[1] While there appears to be a strong link between postpartum psychosis and bipolar disorder,[2] it is estimated… Read More »

Brexanolone for Postpartum Depression: More Data, But Still Some Questions

In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression (PPD).  SAGE-547, now called brexanolone, is an allosteric modulator of GABA-A receptors.  We saw the preliminary results of the Sage Therapeutics Phase 3 Hummingbird Program earlier this year.  Now we have the final set of results… Read More »